Vitiligo, characterised by progressive melanocyte death, can be initiated by exposure to vitiligo-inducing phenols (VIPs). VIPs generate oxidative stress in melanocytes and activate the master antioxidant regulator NRF2. While NRF2-regulated antioxidants are reported to protect melanocytes from oxidative stress, the role of NRF2 in the melanocyte response to monobenzone, a clinically relevant VIP, has not been characterised. We hypothesised that activation of NRF2 may protect melanocytes from monobenzone-induced toxicity. We observed that knockdown of NRF2 or NRF2-regulated antioxidants NQO1 and PRDX6 reduced melanocyte viability, but not viability of keratinocytes and fibroblasts, suggesting that melanocytes were preferentially dependent upon NRF2 activity for growth compared to other cutaneous cells. 
| INTRODUCTION
Vitiligo is an acquired disorder characterised by depigmented skin lesions that spread due to autoimmune targeting of melanocytes.
Vitiligo pathogenesis is complex; however, one widely held hypothesis is that stress responses are compromised in melanocytes from individuals with vitiligo (vitiligo melanocytes). Vitiligo can be initiated following exposure to certain phenolic compounds (vitiligo-inducing phenols or VIPs), which include 4-tertiary butyl phenol (4-TBP) and monobenzone (monobenzyl ether of hydroquinone, MBEH). [1, 2] Both VIPs promote depigmentation in mice engineered to have interfollicular epidermal melanocytes. [3] MBEH, the more potent VIP, [3] is currently the only drug approved by the US FDA to treat vitiligo and is used for complete depigmentation of extensive vitiligo. [4] We investigated the effects of MBEH exposure on normal melanocytes, as a clinically relevant in vitro model for studying melanocyte toxicity, which may underlie vitiligo initiation and lesion spreading. [1, 5, 6] Our goal was to identify survival pathways activated in normal melanocytes and determine if they were dysregulated in vitiligo melanocytes, and thus contribute to disease onset.
We previously reported that expression of the transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2), which regulates cellular response to oxidative stress, is increased in melanocytes dosed with VIPs, [6] similar to responses elicited by other redox-balance disruptors. [7] [8] [9] [10] In the absence of oxidative stress, the Kelch-like ECHassociated protein 1 (KEAP1) repressor complex binds cytoplasmic NRF2, causing ubiquitination and proteasomal degradation of NRF2. [11] Oxidative stress triggers KEAP1 dissociation and nuclear translocation, where NRF2 binds antioxidant response elements (AREs), promoting expression of cytoprotective antioxidants, detoxification proteins and phase II drug metabolising enzymes, including heme oxygenase 1 (HMOX1) and NAD(P)H dehydrogenase, quinone 1 (NQO1). [12, 13] Moreover, NRF2 activation can prevent or treat oxidative stress-and inflammation-mediated diseases. [14, 15] For example, dimethyl fumarate (DMF) induces NRF2 stabilisation, has antiinflammatory properties, is neuroprotective [16, 17] and is approved for treatment of multiple sclerosis. [18] DMF, the most commonly prescribed systemic therapy for psoriasis in Germany, [19] is in clinical trials for treatment of alopecia areata. [20] Although the NRF2-mediated effects of DMF on astrocytes [17] and keratinocytes [21, 22] have been elucidated, DMF effects on melanocytes remain uncharacterised.
Several studies described a cytoprotective role for NRF2 in melanocytes. Upregulation of HMOX1 protected melanocytes against hydrogen peroxide (H 2 O 2 ), [7, 9, 10] while melanoma cells overexpressing NQO1 were resistant against the depigmenting agent rhododendrol. [23] Thus, NRF2 contributes to the melanocyte antioxidant response and may play an important role protecting against MBEHinduced toxicity.
MBEH has pleiotropic effects that contribute to depigmentation in vitiligo, [3, 24, 25] and delineating the protective responses against MBEH-induced cytotoxicity are of clinical importance. In this study, we explored the role NRF2 plays in melanocyte survival following MBEH exposure, a model for vitiligo initiation. Our results demonstrate that NRF2 activation protects melanocytes against MBEH and is a potential therapeutic target for vitiligo. Le Poole, Loyola University Chicago, IL) were also used. [26, 27] Cells were treated with 4-TBP or MBEH as previously described. [6] 4-TBP, MBEH, DMF, N-acetyl cysteine (NAC) and buthionine sulfoximine (BSO) (purchased from Sigma-Aldrich, St. Louis, MO) were dissolved in DMSO. Cells were treated with indicated concentrations of tert-butyl hydroperoxide (t-BHP) for 1 hour followed by incubation in culture medium as a positive control for oxidative stress.
| MATERIALS AND METHODS

| Cell culture and dosing
| Cell viability
Melanocytes (20 000 cells/well), fibroblasts and keratinocytes (5000 cells/well) were plated in 96-well plates and dosed after 24 hours.
Viability was determined using the Cell-Titre 96 Cell Proliferation Assay (MTS) (Promega, Madison, WI) per manufacturer's instructions and confirmed by crystal violet assays as previously reported. [28] Relative viability of vitiligo patient-derived melanocytes and normal control adult melanocytes was measured after 96 hours to account for slower proliferation (75% proliferation of control neonatal melanocytes).
| Determination of subtoxic 4-TBP and MBEH concentrations
Subtoxic concentrations (<20% decrease in viability) of 4-TBP or MBEH were determined based on viability of NHEM following exposure to increasing concentrations of VIPs for 24 and 72 hours. [6] For normal melanocytes, 250 μM 4-TBP or 300 μM MBEH was used unless otherwise specified. siRNA-transfected melanocytes were more sensitive to MBEH; therefore, 200 μM MBEH (equivalent subtoxic dose) was used when dosing for longer than 48 hours. Vitiligo melanocytes were also more sensitive to MBEH compared to normal adult melanocytes; therefore, 100 μM MBEH was used when dosing for longer than 48 hours. A total of 300 μM MBEH was well tolerated by all lines dosed for less than 24 hours.
| Statistical analysis
Data are presented as mean±SD except where indicated. Statistical significance was assessed using unpaired 2-tailed t test using GraphPad Prism. P<.05 was considered statistically significant.
| RESULTS
| NRF2 promotes melanocyte viability
Universally expressed antioxidants such as superoxide dismutase (SOD) and catalase neutralise reactive oxygen species (ROS) generated during oxidative stress in virtually all cell types. SOD converts superoxide anion radicals to H 2 O 2 , which catalase reduces to water and oxygen. Additional antioxidants, such as NRF2-targets NQO1
and PRDX6, participate in ROS neutralisation through scavenging or reducing reactions ( Figure 1A ). NQO1, in addition to having quinone reductase activity, can scavenge superoxide anions directly, [29] while PRDX6 can reduce H 2 O 2 to water. [30] The predominant antioxidant response varies between cell types and is context dependent; thus, we first sought to compare intrinsic NRF2-regulated antioxidant expression in unstressed cutaneous cells.
Antioxidant expression profiles were established utilising melanocyte lines (NHEM and AHEM), fibroblasts (NHDF) and keratinocytes (NHEK). We compared antioxidant expression levels in each line in the absence of exogenous oxidative stress ("unstressed"). Strikingly, although KEAP1-mediated degradation of NRF2 typically maintains NRF2 at undetectable levels, [11] both unstressed melanocyte lines expressed NRF2 ( Figure 1A ). Comparison of nuclear and cytoplasmic expression revealed that NRF2 was predominantly nuclear, while cytoplasmic NRF2 was undetectable (data not shown). Furthermore, melanocytes express abundant basal levels of NQO1 and PRDX6 compared to fibroblasts or keratinocytes ( Figure 1A ). We observed basal expression of NRF2 in two additional NHEM lines and an immortalised NHEM line (data not shown). In contrast, unstressed fibroblasts expressed very low NRF2 and PRDX6 levels, did not express NQO1, but had abundant SOD2 expression ( Figure 1A ). NRF2, NQO1 and PRDX6 expressions were undetectable in keratinocytes, while SOD2 expression was low ( Figure 1A ). Expression of NRF2-target HMOX1 protein was not detected in any unstressed cells (Fig. S1 ).
To determine if NRF2 and its targets impact viability, we down- 
| VIPs activate an antioxidant gene signature in melanocytes
We hypothesised that as both 4-TBP and MBEH induce vitiligo, [1] commonalities between melanocyte transcriptional responses activated would provide insights into genes and biological processes involved in vitiligo initiation. We sought to identify genes upregulated in response to stress by analysis of data from gene expression microarrays. [6] Hierarchical clustering was performed to enhance statistical power. We then compared gene expression in 4-TBP (pooled: 3h/6h) and MBEH (pooled: 6h/24h)-treated melanocytes using subtoxic concentrations sufficient to induce stress and elicit a molecular response without greatly affecting viability (described in [6] ). We identified 354 commonly upregulated genes ( (Table S1 ).
Upregulated genes from the "Response to Oxidative Stress" GO term included NRF2-targets HMOX1 and PRDX6, and genes encoding small mafs (MAFK and MAFF), which heterodimerise with NRF2 localised at AREs [12, 13] (Table S2) . MBEH induced higher expression of oxidative stress genes than 4-TBP (Table S2) , consistent with documented differences in potency. [3, 31] Pathway analysis results suggested a role for NRF2-mediated antioxidant pathways in melanocyte response to VIP-induced stress, which we further characterised.
| VIP exposure activates melanocyte NRF2 antioxidant responses, while constitutive NRF2 activation reduces MBEH-induced toxicity
Melanocytes were treated with 4-TBP (250 μM) or MBEH (300 μM)
as previously described [6] to determine the expression time course of NRF2 and its targets. Nuclear localisation of NRF2 increased within 1 hour of 4-TBP ( S3A), similar to unstressed melanocytes ( Figure 1A ). VIPs also promoted increased mRNA expression of NRF2-target HMOX1 (Fig. S3B ).
HMOX1 levels returned to baseline by 24 hours of 4-TBP exposure, while levels were substantially higher with MBEH exposure and were sustained, even at 24 hours (Fig. S3B ).
4-TBP-induced NRF2 activity (nuclear NRF2 and HMOX1 mRNA expression levels) peaked and returned to baseline within 24 hours (Fig. S3A-B) , suggesting resolution of stress and restored homeostasis. In contrast, MBEH triggered slower, but more robust NRF2 activation, which was sustained at 24 hours (Figure 2A and Fig. S3B ).
The MBEH time course was thus extended to 48 hours ( Figure 2B and Fig. S3C-D) . HMOX1 mRNA expression peaked at 12 hours of MBEH exposure and decreased by 48 hours (Fig. S3C ) consistent with HMOX1 protein expression, which increased within 18 hours of MBEH exposure and returned to basal levels by 48 hours ( Figure 2B ).
MBEH-induced NQO1 mRNA expression also increased ( Figure 2C );
but not NQO1 protein levels (Fig. S3E) . Baseline NQO1 protein levels are already elevated, thus an increase may not be readily determined.
MBEH further induced upregulation of NRF2-targets PRDX6, and the catalytic and regulatory/modifier subunits of γ-glutamylcysteine ligase (GCLC and GCLM, respectively) ( Figure 2C and Fig. S3D ). GCLC and GCLM catalyse the rate-limiting step during glutathione (GSH) biosynthesis. [32] Glutathione peroxidase 1 (GPX1), a potent antioxidant that oxidises reduced GSH and simultaneously neutralises H 2 O 2 , was also upregulated with MBEH exposure (data not shown). This suggests that the cytoprotective response to MBEH-induced stress also involves GSH biosynthesis. In support of this hypothesis, MBEH increased total GSH to levels comparable those of cells treated with the GSH precursor N-acetylcysteine (NAC) ( Figure 2D ). The increase was accompanied by a shift towards oxidised GSH (data not shown). Buthionine sulfoximine (BSO), which inhibits GSH synthesis, effectively depleting GSH ( Figure 2D ). Thus, the melanocyte response to VIP-induced stress may involve multiple NRF2 targets that participate in parallel antioxidant activities.
As subtoxic MBEH doses stimulated NRF2-mediated expression of antioxidants with restoration of homeostasis by 48 hours (Fig.   S3D ), we next investigated whether constitutive activation of NRF2 reduced melanocyte sensitivity to MBEH. Deletion of the negative regulator KEAP1 gene results in constitutive NRF2 activation. [33] We therefore performed siRNA-mediated KEAP1 knockdown (Fig. S3F ), which increased NRF2 activity and promoted a significant increase in HMOX1 (P<.05) and NQO1 (P<.01) expressions (Fig. S3G) . Notably, we observed a significant (P<.001) increase in melanocyte viability with KEAP1 downregulation (Fig. S3H ) and significantly reduced MBEHinduced toxicity (P<.0001) ( Figure 2E ). Thus, the NRF2 response protects melanocytes against MBEH-induced toxicity.
| An impaired NRF2 response contributes to increased MBEH-induced toxicity in vitiligo melanocytes
We observed that normal melanocytes activate the NRF2 and GSH synthesis pathways in response to MBEH exposure, while constitutive NRF2 activation reduced MBEH toxicity. We next investigated whether these pathways were compromised in vitiligo melanocytes.
Both perilesional vitiligo melanocytes (PLVM) and non-lesional vitiligo melanocytes (NLVM) were pigmented and maintained their melanogenic capacity. The immortalised vitiligo PIG3V line however displayed decreased melanogenic capacity and reduced pigmentation.
Intriguingly, untreated PIG3V had increased expression of NRF2
targets HMOX1 and NQO1 compared to normal immortalised melanocytes (PIG1) (Fig. S4) . However, when exposed to increasing concentrations MBEH for 96 hours, NLVM, PLVM and PIG3V were more sensitive to MBEH when compared to normal control melanocytes upregulated HMOX1 after 3 hours ( Figure 3C ). HMOX1 expression was higher in PIG1 than PIG3V following exposure ( Figure 3C ). PIG1 upregulated GSH synthesis pathway genes GPX1, GCLC and GCLM within 1 hour of MBEH exposure; however, expression of these genes was not significantly upregulated in PIG3V ( Figure 3D ). Therefore, vitiligo melanocytes are more sensitive to MBEH, and NRF2 and GSH pathway activations, which is critical for protection against MBEH toxicity, are impaired.
| NRF2 activation by DMF protects normal and vitiligo melanocytes against MBEH-induced toxicity
As constitutive NRF2 activation protects normal melanocytes against MBEH, and vitiligo melanocytes have impaired NRF2 activation, identification of a pharmacologic agent that activates NRF2 for clinical use in vitiligo is of importance. We investigated whether NRF2 activation using the drug DMF protects melanocytes against toxic MBEH doses.
DMF was not toxic in normal melanocytes up to 100 μM; instead, there was a significant (P<.05) increase in cell number following treatment (Fig. S5A) . As expected, treatment of melanocytes with increasing DMF concentrations promoted increased nuclear NRF2 localisation ( Figure 4A ) and HMOX1 mRNA expression ( Figure 4B ).
Remarkably, pretreatment with a low dose of DMF (30 μM) was sufficient to increase NRF2 activation and protect normal melanocytes against exposure to 300 μM MBEH. Moreover, there was a dose-dependent protective effect against high MBEH doses (400-500 μM) ( Figure 4C ). siRNA-mediated NRF2 depletion abolished DMFmediated protection (200 μM MBEH; P<.0001) ( Figure 4D ).
Vitiligo melanocytes have a disrupted oxidant-antioxidant balance and impaired NRF2 response [8, 34] (Figure 3C-D) . We therefore inves- 
| DISCUSSION
In this study, we sought to identify cytoprotective pathways activated by melanocytes in response to agents known to trigger vitiligo. We identified a key role for the NRF2 pathway, in protecting melanocytes against MBEH exposure. Current vitiligo therapies aim to promote repigmentation by targeting autoimmune responses or stimulating melanocyte migration into lesions. [35] [36] [37] While the use of antioxidants to improve repigmentation is documented, [38] therapies that effectively ameliorate melanocyte oxidative stress-a known mediator of disease progression [39, 40] -are not currently approved.
Melanocytes activate the NRF2 response when exposed to oxidative stress [7, 41] and vitiligo melanocytes have been reported to exhibit compromised activation of the NRF2 response. [8, 42] Comparison of the antioxidant profile of cutaneous cells revealed that NRF2 and NRF2-regulated antioxidants promoted melanocyte viability, but played a lesser role in determining keratinocyte and fibroblast viability. Multiple studies reported more robust NRF2 activation in melanocytes compared to keratinocytes after exposure to chemical stressors [41] or ultraviolet radiation. [43] Comparison of melanocytes to other cutaneous cells in the absence of exogenous stressors revealed that while melanocytes had lower basal expression of SOD2, they expressed abundant NQO1, which can alternatively scavenge superoxide radicals. Most cell types use SOD as their first line of defense against superoxide anions because it has better reducing enzyme activity. However, cells that have low SOD levels, such as cardiovascular tissues [44] and perhaps melanocytes, utilise NQO1. NQO1 reduces quinone compounds such as DOPA-quinone and indole 5,6 quinone, which are intermediates of melanin synthesis; [45] therefore, melanocytes may maintain high basal NQO1 levels to quickly scavenge quinone by-products that leak into the cytosol should the melanosome be compromised. [46] Moreover, melanocytes preferentially expressed PRDX6, which reduces hydrogen and lipid peroxides. Melanocytes may also require PRDX6 as an immediate defense against melanogenesis by-products. Interestingly, NQO1 and PRDX6 downregulation did not affect fibroblasts and keratinocytes viability except in following exposure to exogenous oxidative stress, suggesting that in the absence of oxidative stress, NRF2 targets have a cytoprotective function in melanocytes, but not in fibroblasts or keratinocytes.
In addition to NRF2 expression in unstressed melanocytes, melanocytes further activated NRF2 upon exposure to sublethal doses of VIPs. We employed an in vitro model for vitiligo initiation, in which normal melanocytes were exposed to subtoxic 4-TBP and MBEH doses, and evaluated the cellular responses. Exposure to 4-TBP initiated a rapid NRF2/HMOX1 response, which quickly resolved to basal levels. However, MBEH exposure triggered a more expansive NRF2 response, upregulating additional NRF2 targets including HMOX1, NQO1, PRDX6, GCLC and GCLM. As MBEH can form semiquinone radicals, we anticipated upregulation of NQO1, a quinone reductase. [29, 47] Another mechanism for quinone reduction is through GSH conjugation. [48] As GCLC and GCLM catalyse the rate-limiting step in GSH synthesis, we hypothesised their increased expression would promote increased GSH levels to combat MBEH-induced toxicity. As predicted, GSH levels increased in response to subtoxic MBEH doses. MBEH, which is more potent than 4-TBP, [3] induces depigmentation through numerous mechanisms including cytotoxic T cell-mediated autoimmune destruction of melanocytes, ROS production, quinone haptenisation and necrotic cell death. [25] Our findings suggest that increased expres- [7] [8] [9] [10] it is therefore possible that the pathway is maximally activated with 30 μM DMF, and that 50 μM DMF is not more protective and instead excess DMF reduces efficacy. Of clinical importance, DMF was protective at doses that were not themselves toxic to melanocytes. This is in contrast to the inherent toxicities of other NRF2 activators, such as phytochemical carnosic acid [23] and curcumin (our unpublished observation). Although clinical trials will be required to establish the safest dose and efficacy of DMF in vitiligo patients, our study showed a protective effect against a potent vitiligo inducer using lower concentrations of DMF than those currently approved for psoriasis or multiple sclerosis. In addition, constitutive and chronic NRF2 activation can be detrimental; [33] thus, promoting a transient NRF2 increase using DMF would translate into clinical practice more effectively. DMF has additional immunomodulatory properties [16] that may further protect melanocytes in vivo and prove beneficial for modulating autoimmune-mediated progression of vitiligo.
Monotherapies targeting oxidative stress have been ineffective in vitiligo to date. This is potentially due to the focus on general oxidative stress amelioration, rather than targeting specific pathways activated by melanocytes in response to stressors with pleiotropic effects, such as MBEH. For instance, despite reports suggesting that catalase protects melanocytes undergoing stress, [5] topical treatment with pseudocatalase has not prevented disease progression. Although melanocytes from individuals with vitiligo demonstrate compromised antioxidant activity, [34, 49, 50] dysfunctional NRF2 activity [8, 42] may be more disruptive than the imbalance of other antioxidants. Vitiligo melanocytes have low nuclear NRF2 expression compared to normal melanocytes. [42] Thus, further activating the NRF2 response in vitiligo melanocytes using DMF may promote increased nuclear NRF2. DMF may be a useful adjuvant therapy that reduces active depigmentation and protects melanocytes that are repopulating lesional areas following treatment with modalities such as UVB. In summary, we demonstrated that the NRF2 response contributes to melanocyte survival and protects against MBEH in both normal and vitiligo melanocytes.
We thus introduce a potential therapeutic strategy-activating the NRF2 response using DMF-for the treatment of vitiligo.
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